Compare Biogen Inc (BIIB) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Western Union Co — how do they compare? Biogen Inc trades at $204.08 (market cap $30.13B), while Western Union Co trades at $6.95 (market cap $2.20B). The key difference: Biogen Inc is far larger — about 13.7× Western Union Co's market cap, and Western Union Co pays a 13.33% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WU | |
|---|---|---|
Market Cap | $30.13B | $2.20B |
Sector | Health | Technology |
52-Week High | $216.63 | $10.28 |
52-Week Low | $128.93 | $6.36 |
Enterprise Value | $37.20B | $2.10B |
Dividend Yield | — | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Western Union (WU) trades at $7.03, down 0.71% on the day, with a bearish technical outlook and recent earnings misses. The stock shows low valuation multiples (P/E 5.69, P/S 0.56) and strong profitability metrics (ROE 43.97%), but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent news highlights challenges in retail money transfers and a new digital initiative with Rain.
The investment outlook is cautious due to declining revenue, earnings volatility, and bearish analyst sentiment. Opportunities exist from deep value metrics and dividend yield, but risks include competitive pressures and execution challenges in digital transformation. The consensus price target is $7.14, suggesting limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
